All Comments by Philip Scheltens
Go to another page:
- 1
- 2
- Direct-to-Consumer Alzheimer’s Blood Test Opens Pandora’s Box
- No Easy Answers on Clinical Meaningfulness of Alzheimer’s Treatments
- CMS Plans to Limit Aduhelm Coverage to Clinical Trials
- Aduhelm Administration Remains a Trickle, ARIA a Concern
- A New Era of Alzheimer’s Treatment
- In Phase 2, Donanemab Curbs Cognitive Decline in Early Alzheimer’s
- Aducanumab Still Needs to Prove Itself, Researchers Say
- In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned
- Coronavirus Takes Its Toll on Alzheimer’s Clinical Studies
- Plaques, Tangles Throw Off the Brain’s Rhythms
- Topline Result for First DIAN-TU Clinical Trial: Negative on Primary
- Dementia Researchers Commend FDA Crackdown on Supplement Hype
- Roche Pulls Plug on Two Phase 3 Trials of Crenezumab
- $100M IDEAS: CMS Blesses Study to Evaluate Amyloid Scans in Clinical Practice
- The EMA Deems Brain Atrophy Valid Trial Selection Measure